Blood pressure variability supersedes heart rate variability as a real-world measure of dementia risk

Joseph E. Ebinger, Matthew Driver, Tzu Yu Huang, Jose Magraner, Patrick Botting, Minhao Wang, Peng‐Sheng Chen, Natalie A. Bello, David Ouyang, John Theurer, Susan Cheng, Zaldy S. TanScientific 2024 · DOI

Abstract

Blood pressure variability (BPV) and heart rate variability (HRV) have been associated with Alzheimer's Disease and Related Dementias (ADRD) in rigorously controlled studies. However, the extent to which BPV and HRV may offer predictive information in real-world, routine clinical care is unclear. In a retrospective cohort study of 48,204 adults (age 54.9 ± 17.5 years, 60% female) receiving continuous care at a single center, we derived BPV and HRV from routinely collected clinical data. We use multivariable Cox models to evaluate the association of BPV and HRV, separately and in combination, with incident ADRD. Over a median 3 [2.4, 3.0] years, there were 443 cases of new-onset ADRD. We found that clinically derived measures of BPV, but not HRV, were consistently associated with incident ADRD. In combined analyses, only patients in both the highest quartile of BPV and lowest quartile of HRV had increased ADRD risk (HR 2.34, 95% CI 1.44-3.81). These results indicate that clinically derived BPV, rather than HRV, offers a consistent and readily available metric for ADRD risk assessment in a real-world patient care setting. Thus, implementation of BPV as a widely accessible tool could allow clinical providers to efficiently identify patients most likely to benefit from comprehensive ADRD screening.

Introduction

Alzheimer’s Disease and Related Dementias (ADRD) are often diagnosed too late for meaningful intervention. While researchers have long known that autonomic dysfunction—measured via fluctuations in blood pressure and heart rate—correlates with cognitive decline, most evidence comes from highly controlled clinical trials.

In the "real world," clinical data is inherently noisy: blood pressure is often measured hastily, cuff sizes vary, and patients might be stressed. This study sought to determine if the predictive "signal" of blood pressure variability (BPV) and heart rate variability (HRV) survives this noise in a standard electronic health record (EHR) environment, specifically to identify which metric is more useful for clinicians triaging patients for comprehensive dementia screening.

Methods

The researchers conducted a retrospective cohort study using longitudinal data from Cedars-Sinai Medical Center in Los Angeles. The study analyzed two primary groups:

  • The BP Cohort: 48,204 adults who had at least one outpatient visit per year between 2013 and 2016.
  • The EKG Cohort: A subset of 7,270 patients who also had qualifying EKG data.

BPV was calculated using Variation Independent of the Mean (VIM), a non-linear transformation that ensures the variability metric isn't just a proxy for high average blood pressure. HRV was derived from EKGs (specifically the RMSSD of Q-Q intervals) rather than simple pulse checks, as EKG data is less susceptible to measurement error. Multivariable Cox proportional hazards models were used to evaluate the association of these metrics with incident ADRD during a surveillance period from 2017 to 2019, adjusting for age, sex, race, smoking status, and comorbidities.

Results

The study found that BPV is a significantly more robust predictor of dementia risk than HRV when using real-world clinical data. In the primary cohort, higher systolic BPV was associated with a Hazard Ratio (HR) of 1.24 (95% CI 1.14–1.35) for new-onset dementia, while HRV alone showed no significant association (HR 1.00).

Hazard ratios for incident ADRD across pooled and stratified analyses for BPV and HRV.

As shown in the stratified analyses, the predictive value of BPV remained consistent across various demographic strata, including age, sex, and race. One of the most significant findings was the synergistic risk: patients in the highest quartile of BPV and the lowest quartile of HRV faced more than double the risk of dementia (HR 2.34, 95% CI 1.44–3.81) compared to the low-risk reference group.

Discussion

These results indicate that clinically derived BPV, rather than HRV, offers a consistent and readily available metric for ADRD risk assessment in a real-world setting. The findings suggest that longitudinal variability across years of visits remains a powerful biomarker despite the "noise" of routine clinical measurements.

The authors hypothesize that BPV may be a "top-down" driver of neurovascular damage (causing brain injury), whereas HRV might be a "downstream" symptom of autonomic failure that only appears after dementia has significantly progressed. While limited by its single-center nature and reliance on ICD codes, the study suggests that BPV could be integrated into EHR-based automated flags to alert providers to high-risk patients, triggering earlier screening and intervention.

Summary updated

Abstract

Blood pressure variability (BPV) and heart rate variability (HRV) have been associated with Alzheimer's Disease and Related Dementias (ADRD) in rigorously controlled studies. However, the extent to which BPV and HRV may offer predictive information in real-world, routine clinical care is unclear. In a retrospective cohort study of 48,204 adults (age 54.9 ± 17.5 years, 60% female) receiving continuous care at a single center, we derived BPV and HRV from routinely collected clinical data. We use multivariable Cox models to evaluate the association of BPV and HRV, separately and in combination, with incident ADRD. Over a median 3 [2.4, 3.0] years, there were 443 cases of new-onset ADRD. We found that clinically derived measures of BPV, but not HRV, were consistently associated with incident ADRD. In combined analyses, only patients in both the highest quartile of BPV and lowest quartile of HRV had increased ADRD risk (HR 2.34, 95% CI 1.44-3.81). These results indicate that clinically derived BPV, rather than HRV, offers a consistent and readily available metric for ADRD risk assessment in a real-world patient care setting. Thus, implementation of BPV as a widely accessible tool could allow clinical providers to efficiently identify patients most likely to benefit from comprehensive ADRD screening.
BibTeX
@inproceedings{ebinger2024blood,
  author = {Joseph E. Ebinger and Matthew Driver and Tzu Yu Huang and Jose Magraner and Patrick Botting and Minhao Wang and Peng‐Sheng Chen and Natalie A. Bello and David Ouyang and John Theurer and Susan Cheng and Zaldy S. Tan},
  title = {{Blood pressure variability supersedes heart rate variability as a real-world measure of dementia risk}},
  booktitle = {Scientific},
  year = {2024},
  doi = {10.1038/s41598-024-52406-8},
}
Figure